Article
Biotechnology & Applied Microbiology
Jia-Yin Chen, Xu-Yun Huang, Fei Lin, Qi You, Yu-Ting Xue, Bin Lin, Qing-Shui Zheng, Yong Wei, Xue-Yi Xue, Xiao-Dong Li, Dong-Ning Chen, Ning Xu
Summary: This study identified tumor-associated macrophages (TAMs) related molecular subtypes and developed a prognostic model for prostate cancer (PCa) based on TAMs. Three TAMs related molecular subtypes were identified, which were associated with prognosis, clinicopathological characteristics, PD-L1 expression levels, and tumor microenvironment. The developed prognostic model showed excellent predictive performance for biochemical recurrence-free survival in PCa.
Article
Cell Biology
Zhengtong Lv, Jianlong Wang, Xuan Wang, Miao Mo, Guyu Tang, Haozhe Xu, Jianye Wang, Yuan Li, Ming Liu
Summary: A risk model containing nine ferroptosis-related genes was constructed in this study, demonstrating strong prognostic and therapeutic predictive power in prostate cancer. The higher risk score calculated by the model was significantly associated with adverse clinicopathological characteristics, immune infiltration, probability of biochemical recurrence, and treatment response in PCa. The findings provide new insights and potential clinical applications of ferroptosis in PCa.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Jiao-chen Luan, Qi-jie Zhang, Kai Zhao, Xiang Zhou, Liang-yu Yao, Tong-tong Zhang, Teng-yue Zeng, Jia-dong Xia, Ning-hong Song
Summary: This study utilized immune-associated genes to predict biochemical recurrence and guide treatment in localized prostate cancer patients after radical prostatectomy. A novel immune-associated genes signature was identified and proven to be an independent prognostic factor for recurrence, and a predictive nomogram was constructed based on this signature. Functional enrichment analysis revealed crucial immune-related pathways enriched in high-risk patients.
Article
Oncology
Shi-Heng Wang, Shu-Pin Huang, Yi-Jiun Pan, Po-Chang Hsiao, Chia-Yang Li, Lih-Chyang Chen, Chia-Cheng Yu, Chao-Yuan Huang, Victor C. Lin, Te-Ling Lu, Bo-Ying Bao
Summary: The genetic predisposition to breast cancer is associated with a low risk of prostate cancer recurrence, indicating a potential link between breast cancer susceptibility variants and prostate cancer outcomes. Further studies are needed to investigate the role of breast cancer-related genetic factors and estrogen signaling in the progression of prostate cancer.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Oncology
Zhaojun Yu, Haichao Chao, Fanghua Xu, Huanhuan Deng, Leihong Deng, Zhen Song, Tao Zeng
Summary: This study identified BIRC5 as a potential prognostic biomarker related to biochemical recurrence (BCR) in prostate cancer (PCa). A nomogram was constructed to predict BCR-free survival (BFS) and assist with clinical decision-making.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Daojun Lv, Xiangkun Wu, Xi Chen, Shuxin Yang, Wenzhe Chen, Ming Wang, Yongda Liu, Di Gu, Guohua Zeng
Summary: A novel immune-related gene-based prognostic signature (IRGPS) was identified to predict biochemical recurrence in prostate cancer patients. High-risk patients showed higher levels of regulatory T cells and M2 macrophages, while low-risk patients had higher levels of resting memory CD4 T cells and resting mast cells. A strong correlation was found between IRGPS and specific clinicopathological features.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Medicine, General & Internal
Chia -Yen Lin, Chun -Li Wang, Shian-Shiang Wang, Cheng-Kuang Yang, Jian-Ri Li, Chuan-Shu Chen, Sheng-Chun Hung, Kun-Yuan Chiu, Chen-Li Cheng, Yen-Chuan Ou, Shun-Fa Yang
Summary: The study investigated the associations between WWOX polymorphisms, clinicopathologic features of prostate cancer, and risk of postoperative biochemical recurrence. The findings suggest that WWOX SNPs are significantly associated with aggressive pathologic features of PCa and an elevated risk of post-RP biochemical recurrence.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2023)
Article
Medicine, General & Internal
Zhongyou Xia, Haolin Liu, Shicheng Fan, Hongtao Tu, Yongming Jiang, Hai Wang, Peng Gu, Xiaodong Liu
Summary: This study aimed to establish a mitochondrial respiratory gene-based risk model to predict the biochemical recurrence (BCR) of patients with prostate cancer (PCa) after radical prostatectomy. Through analyzing RNA sequencing data, differentially expressed mitochondrial respiratory and BCR-related genes were identified and used to construct a risk model. A nomogram was established, and further analyses revealed the relationship between the risk model and PPAR signaling pathway, cholesterol metabolism, and immune cell types. The risk model also had an impact on the effectiveness of certain cancer drugs.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Jessica M. Logan, Ashley M. Hopkins, Carmela Martini, Alexandra Sorvina, Prerna Tewari, Sarita Prabhakaran, Chelsea Huzzell, Ian R. D. Johnson, Shane M. Hickey, Ben S. -Y. Ung, Joanna Lazniewska, Robert D. Brooks, Courtney R. Moore, Maria C. Caruso, Litsa Karageorgos, Cara M. Martin, Sharon O'Toole, Laura Bogue Edgerton, Mark P. Ward, Mark Bates, Stavros Selemidis, Adrian Esterman, Sheena Heffernan, Helen Keegan, Sarah Ni Mhaolcatha, Roisin O'Connor, Victoria Malone, Marguerite Carter, Katie Ryan, Andres Clarke, Nathan Brady, Sonja Klebe, Hemamali Samaratunga, Brett Delahunt, Michael J. Sorich, Kim Moretti, Lisa M. Butler, John J. O'Leary, Douglas A. Brooks
Summary: A novel biomarker panel (Appl1, Sortilin and Syndecan-1) was found to be a strong independent predictor for both clinical and biochemical recurrence outcomes, with higher prediction performance than traditional grading. The study also found that biomarker-assisted assessment had better predictive performance for evaluating the risk of biochemical recurrence and clinical recurrence in patients with prostate cancer.
Article
Oncology
Saisai Chen, Kai Lu, Yue Hou, Zonghao You, Chuanjun Shu, Xiaoying Wei, Tiange Wu, Naipeng Shi, Guangyuan Zhang, Jianping Wu, Shuqiu Chen, Lihua Zhang, Wenchao Li, Dingxiao Zhang, Shenghong Ju, Ming Chen, Bin Xu
Summary: The study found that high expression of YY1 is closely associated with M2 macrophages in prostate cancer, promoting tumor development. The study also revealed that treatment targeting YY1 can suppress tumor metastasis and generate synergistic anti-tumor effects. Furthermore, the study revealed that YY1 upregulates IL-6 expression by regulating enhancer-promoter interactions, thereby promoting tumor progression.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Immunology
Gaozhen Jia, Xingjie Wang, Wenbo Wu, Yu Zhang, Shaoan Chen, Jing Zhao, Wei Zhao, Weiguo Li, Xiaowen Sun, Bangmin Han
Summary: This study reveals that prostate cancer cells promote the development of tumors by modulating macrophage polarization and identifies the crucial roles of METTL3 and STAT6 in this process. Additionally, the study discovers that LXA4 acts as a signaling molecule in this pathway, activating STAT6 by inhibiting METTL3.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Lin Li, Rakesh Shiradkar, Patrick Leo, Ahmad Algohary, Pingfu Fu, Sree Harsha Tirumani, Amr Mahran, Christina Buzzy, Verena C. Obmann, Bahar Mansoori, Ayah El-Fahmawi, Mohammed Shahait, Ashutosh Tewari, Cristina Magi-Galluzzi, David Lee, Priti Lal, Lee Ponsky, Eric Klein, Andrei S. Purysko, Anant Madabhushi
Summary: This study developed and validated an integrated radiomic-clinicopathologic nomogram (RadClip) for predicting biochemical recurrence free survival (bRFS) and adverse pathology (AP) in prostate cancer patients. RadClip showed better predictive performance for bRFS and AP compared to Decipher and CAPRA.
Article
Pathology
Qianwei Xing, Shouyong Liu, Jiaochen Luan, Yi Wang, Limin Ma
Summary: This study established a model for predicting BCR in prostate cancer patients using RBPs, demonstrating its predictive performance and the importance of being an independent prognostic factor. External and internal verification showed that patients with high riskScores had shorter time to BCR.
PATHOLOGY RESEARCH AND PRACTICE
(2021)
Article
Oncology
Rui Zhou, Yuanfa Feng, Jianheng Ye, Zhaodong Han, Yuxiang Liang, Qingbiao Chen, Xiaoming Xu, Yuhan Huang, Zhenyu Jia, Weide Zhong
Summary: This study analyzed gene expression in tumor-adjacent normal tissues and identified a 10-gene prognostic model that accurately predicts biochemical recurrence-free survival in prostate cancer patients. The predictive ability was validated using an independent cohort. The prognostic genes in the tumor microenvironment were enriched in the p53 signaling pathway, indicating potential crosstalk mechanisms between tumor and its microenvironment in prostate cancer progression.
FRONTIERS IN ONCOLOGY
(2021)
Article
Urology & Nephrology
Linda My Huynh, Emily Keit, Erica Huang, Raymond Ceja Carrillo, Thomas E. Ahlering, Shawna Boyle, Charles A. Enke, Michael Baine
Summary: The study assessed the impact of metformin on biochemical failure in localized prostate cancers treated with radical prostatectomy or radiation therapy. It found that metformin was associated with a significant risk reduction in biochemical failure overall and at 5 years following primary treatment, suggesting the need for further investigations into metformin's role in disease-free survival in men with localized prostate cancer.
Article
Oncology
Yi Wang, Rong Cong, Shouyong Liu, Bingye Zhu, Xing Wang, Qianwei Xing
Summary: Our study demonstrated that METTL14 could serve as a favorable prognostic factor in clear cell renal cell carcinoma (ccRCC), being associated with better overall survival. Additionally, significant enrichment of METTL14 in multiple signaling pathways was identified, and a prognostic signature integrating METTL14 expression and clinicopathologic variables was established to predict survival probabilities in ccRCC. Furthermore, a METTL14-based risk score was developed with improved prognostic accuracy.
CANCER CELL INTERNATIONAL
(2021)
Article
Oncology
Shouyong Liu, Yi Wang, Chenkui Miao, Qianwei Xing, Zengjun Wang
Summary: CDCA7 is overexpressed in ccRCC and associated with shorter overall survival. It is identified as an independent prognostic factor and closely related to microsatellite instability, tumor mutational burden, and immunity.
CANCER CELL INTERNATIONAL
(2021)
Article
Cell Biology
Xiaomin Cai, Wenjin Qiu, Mengshu Qian, Shuang Feng, Chenghao Peng, Jiale Zhang, Yi Wang, Yuhai Wang
Summary: CFI is overexpressed in glioma and is associated with poor outcomes, serving as a potential prognostic biomarker and driving malignant progression in glioma.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Yi Wang, Yinhao Chen, Bingye Zhu, Limin Ma, Qianwei Xing
Summary: This study established and validated a prognostic model for predicting overall survival in ccRCC patients based on apoptosis-related genes, providing clinicians with a standardized tool for prognostic assessment. Future prospective studies are needed to further validate these findings.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Oncology
Qianwei Xing, Tengyue Zeng, Shouyong Liu, Hong Cheng, Limin Ma, Yi Wang
Summary: A novel signature based on 10 prognostic GRGs was successfully established and externally and internally validated for predicting OS of ccRCC, assisting clinicians in better predicting patients' survival.
Article
Cell Biology
Deng Li, Shiwei Liu, Jie Xu, Lei Chen, Chaoliang Xu, Feiteng Chen, Zijie Xu, Yu Zhang, Shujie Xia, Yi Shao, Yi Wang
Summary: Through bioinformatic analyses, it was found that CHAC1 has the potential to predict malignancy and prognosis in KIRC. Various analyses confirmed that up-regulated CHAC1 is an independent risk factor for poor prognosis in KIRC, and a model was constructed to predict patient survival rates. CHAC1 was also found to be associated with immune pathway markers and checkpoint genes.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2021)
Article
Medicine, Research & Experimental
Qianwei Xing, Jiaochen Luan, Shouyong Liu, Limin Ma, Yi Wang
Summary: The aim of this article was to construct a prognostic model using RNA-binding proteins (RBPs) to predict overall survival for patients with clear cell renal cell carcinoma (ccRCC), as well as explore its associations with immune infiltration. The study successfully identified six RBPs as a robust prognostic signature, which was strongly related to ccRCC patients' survival and clinicopathological characteristics. The established model also displayed significant associations with immune infiltration.
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES
(2022)
Article
Pathology
Qianwei Xing, Shouyong Liu, Jiaochen Luan, Yi Wang, Limin Ma
Summary: This study established a model for predicting BCR in prostate cancer patients using RBPs, demonstrating its predictive performance and the importance of being an independent prognostic factor. External and internal verification showed that patients with high riskScores had shorter time to BCR.
PATHOLOGY RESEARCH AND PRACTICE
(2021)
Article
Oncology
Yicong Yao, Yi Wang, Denglong Wu, Baoying Hu
Summary: The increased expression of CDC6 is potentially a poor prognostic factor in ccRCC patients. High CDC6 expression is correlated with malignant characteristics of tumors and multiple signaling pathways, as well as with immune-related factors, tumor microenvironment, and immune cell infiltration. The results from the TCGA database also show a significant relationship between CDC6 and immune checkpoint molecules and immune cells.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Hong Cheng, Bin Xu, Lijie Zhang, Yi Wang, Ming Chen, Shuqiu Chen
Summary: The study demonstrated that bortezomib could reduce the levels of donor-specific antibodies, alleviate inflammation in grafts, modulate immune cell ratios, and affect cytokine expression to slow down the rejection process. By targeting Atg5, bortezomib may play a key role in attenuating antibody-mediated rejection.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2021)
Article
Immunology
Yi Wang, Hao Ji, Bingye Zhu, Qianwei Xing, Huyang Xie
Summary: Due to tumor molecular heterogeneity, similar ccRCC patients may have different survival rates. This study identified three metabolic subtypes of ccRCC based on novel metabolism-associated genes (MAGs) and explored their association with immune landscapes and prognosis. The results showed that these subtypes were associated with various immune markers and could predict immunotherapeutic responses.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Yaoyu Yu, Guihua Chen, Chao Jiang, Tuanjie Guo, Heting Tang, Zhihao Yuan, Yi Wang, Xiangyin Tan, Jinyuan Chen, Encheng Zhang, Xiang Wang
Summary: This study used bioinformatics analysis to confirm that the high expression of USP31 in clear cell renal cell carcinoma is associated with poor prognosis, and found that USP31 may be related to immunity and can serve as a potential biomarker for predicting prognosis and immune response in kidney cancer patients.
JOURNAL OF GENE MEDICINE
(2023)
Article
Multidisciplinary Sciences
Shiwei Liu, Jing Zhai, Deng Li, Yu Peng, Yi Wang, Bo Dai
Summary: This study established a prognostic signature of autophagy-dependent ferroptosis regulatory molecules (ADFRMs) in bladder urothelial carcinoma (BLCA) and identified TRIB3 and WIPI1 as potential prognostic genes. The ADFRMs signature showed an acceptable capacity for survival prediction in BLCA.
Article
Genetics & Heredity
Yi Wang, Xinyu Zhang, Guihua Chen, Qianwei Xing, Bingye Zhu, Xiang Wang
Summary: This study aimed to explore the roles of FDX1 in kidney renal clear cell carcinoma (KIRC) and its potential molecular mechanisms using scRNA-sequencing and bulk RNA-sequencing analyses. FDX1 was found to be lowly expressed in KIRC and its elevated expression was associated with better overall survival prognosis. Gene set enrichment analysis identified seven pathways strongly associated with FDX1 in KIRC. Furthermore, FDX1 was significantly related to immunity and patients with low expression of FDX1 might be more sensitive to immunotherapies.
GENES AND IMMUNITY
(2023)
Article
Biotechnology & Applied Microbiology
Gang Wang, Fangfang Qu, Shouyong Liu, Jincai Zhou, Yi Wang
Summary: This study revealed that NOP2 might be a potential prognostic factor for overall survival in ccRCC, and it was significantly associated with immunity, MSI, and TMB.